A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours

Background: This phase I study was performed to evaluate the safety, tolerability, and efficacy of the oral matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced solid tumours, and to identify the maximum tolerated dose and dose for use in subsequent studies. Patients and methods:...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2000-12, Vol.11 (12), p.1579-1584
Hauptverfasser:	Hirte, H., Goel, R., Major, P., Seymour, L., Huan, S., Stewart, D., Yau, J., Arnold, A., Holohan, S., Waterfield, B., Bates, S., Bennett, K., Walsh, W., Elias, I.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - pharmacokinetics Biological and medical sciences Biphenyl Compounds Chemotherapy Dose-Response Relationship, Drug dosing Female Humans inhibitor Male matrix metalloproteinase Medical sciences Middle Aged Neoplasms - drug therapy Organic Chemicals pharmacokinetics Pharmacology. Drug treatments Phenylbutyrates solid tumours toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!